Basics Verve Therapeutics, Inc. IPO Date: July 17, 2021 Sector: Healthcare Industry: Biotech Market Cap: $427.44M Activated in VL: True Average Daily Range Avg Daily Range: $0.81 | 3.94% Avg Daily Range (30 D): $0.23 | 4.72% Avg Daily Range (90 D): $0.26 | 4.72% Institutional Daily Volume Avg Daily Volume: .98M Avg Daily Volume (30 D): 2.69M Avg Daily Volume (90 D): 2.48M Trade Size Avg Trade Size (Sh.): 81 Avg Trade Size (Sh.) (30 D): 114 Avg Trade Size (Sh.) (90 D): 118 Institutional Trades Total Inst.Trades: 1,410 Avg Inst. Trade: $2.02M Avg Inst. Trade (30 D): $1.21M Avg Inst. Trade (90 D): $1.12M Avg Inst. Trade Volume: .13M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.41M Avg Closing Trade (30 D): $1.11M Avg Closing Trade (90 D): $1.07M Avg Closing Volume: 160.28K     News May 28, 2025 @ 11:00 AM Verve Therapeutics to Participate in Upcoming Inve... Source: N/A May 19, 2025 @ 2:56 PM Bio/Pharmaceutical Outsourcing Report, March 2025 ... Source: Researchandmarkets.Com Apr 18, 2025 @ 10:36 PM Why Verve Therapeutics Zoomed 40% Higher This Week... Source: Eric Volkman Apr 15, 2025 @ 4:43 PM Why Verve Therapeutics Is Skyrocketing Today Source: Keith Noonan Apr 11, 2025 @ 11:00 AM Verve Therapeutics Receives U.S. FDA Fast Track De... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-2.11 $-.35 $-.58 Diluted EPS $-2.11 $-.35 $-.58 Revenue $ 59.61M $ 32.98M $ 13.08M Gross Profit $ $ $ Net Income / Loss $ -181.01M $ -31.03M $ -50.04M Operating Income / Loss $ -208.45M $ -36.64M $ -56.07M Cost of Revenue $ $ $ Net Cash Flow $ -47.65M $ -76.01M $ 13.85M PE Ratio